Analysis shows increased risk of early stroke with new-onset atrial fibrillation post-TAVR

(Society for Cardiovascular Angiography and Interventions) Results from 'Effect of bivalirudin versus unfractionated heparin in patients with baseline or new-onset atrial fibrillation in transcatheter aortic valve replacement: From the BRAVO-3 randomized trial' were presented today as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2017 Scientific Sessions in New Orleans.

from EurekAlert! - Social and Behavioral Science http://ift.tt/2r5ZNy6